The “Anti-fungal Drugs Market” report 2019 delivers up-to-date information about market changes and prospective threats, as well as in-depth knowledge of products and services, which can help in planning and in executing category management activities. Moreover, it focuses on the cost-saving aspects of procurement and on providing insights that can lead to optimization of category spend.
Get a Sample Copy of the Report At – https://www.industryresearch.co/enquiry/request-sample/14099134
Top Key Players of Anti-fungal Drugs Market Are:
Reasons to buy:
- In-depth analysis of the market on the global and regional level.
- Major changes in market dynamics and competitive landscape.
- Segmentation on the basis of type, application, geography and others.
- Historical and future market research in terms of size, share, growth, volume & sales.
- Major changes and assessment in market dynamics & developments.
- Industry size & share analysis with industry growth and trends.
- Emerging key segments and regions
- Key business strategies by major market players and their key methods.
- The research report covers size, share, trends and growth analysis of the Anti-fungal Drugs Market on the global and regional level.
Inquire or Share Your Questions If Any Before the Purchasing This Report – https://www.industryresearch.co/enquiry/pre-order-enquiry/14099134
Scope of the Report:
Anti-fungal Drugs market covers the outlook for overall market status, size and share. The report provides complete coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Anti-fungal Drugs market report also presents the market competition landscape and a corresponding detailed analysis of the major vendor in the market.
Key Market Trends:
Azoles Segment under Drug Type Segmentation is expected to be the Fastest Growing Market over the Forecast Period
Anti-fungal drug research is gaining momentum, owing to the development of new antifungal drugs using the azole group. Azoles are synthetic and semi-synthetic compounds, widely used for superficial and invasive fungal infections. The drugs are used to treat thrush, yeast infection, candidiasis, aspergillosis, tinea versicolor, athlete’s foot, jock itch, ringworm, nail fungus, fungal infections, systemic mycosis, and seborrheic dermatitis. The azole anti-fungal group includes two classes, namely the triazoles (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) and the imidazoles (ketoconazole). Triazoles have a broad range of applications in the treatment of superficial and systemic fungal infections. The azole group offers a broad spectrum of activity and improved safety levels. The drugs have fewer adverse effects, less serious drug interactions, and improved absorption and distribution properties. The aforementioned benefits of azoles have contributed toward their dominance over other segments. The azoles are currently the most widely used and studied class of antifungal agents. The drugs are available in different formulations (oral tablet, oral capsule, cream, dandruff shampoo, sterile IV solution, lotion, vaginal cream, and tablet). The advancements and innovations in such potential drugs fuel the competitiveness of the pharmaceutical market. Sales of both the established agents and newly launched anti-fungal agents are significant. The issue with antifungal drug resistance has prompted further investigations of the underlying molecular mechanisms. Increased resistance is being observed amongst the Candida and Aspergillus species, particularly to azoles, which is believed to be driven by the use of azoles in agriculture. Increasing drug resistance is anticipated to provide an opportunity for other drug classes to capture the market.
North America is expected to account for the Largest Market Share in the Global Market
Fungal diseases in the United States have presented challenges to the healthcare authorities in the country. People across the world, including in the United States, have developed resistance to the available medicines. According to the Centers for Disease Control and Prevention (CDC), resistance to certain types of Candida (which happens to be the most common cause of healthcare-associated bloodstream infections in the United States) has been noticed. Approximately 7% of all the Candida bloodstream isolates tested at CDC are resistant to fluconazole. This observation has remained fairly constant over the last two decades. However, echinocandin resistance has been on the rise. In addition, the incidences of multi-drug resistance have increased in the country. Moreover, thirteen cases of Candida auris (which can cause invasive infections and is resistant to anti-fungal drugs) have been identified in the United States. According to the CDC, out of the thirteen, seven of the cases occurred between May 2013 and August 2016. The immunocompromised, aged population is on the rise in the United States. There were close to 46 million people aged 65 years and above in 2015. The population is expected to double (over 98 million) by 2060. This will represent about 24% of the total population in the country. This population is more susceptible to chronic diseases, such as cancer, thereby compromising the immune system. Thus, the population would be more susceptible to other diseases, like fungal diseases. The increasing incidences of resistance and immunocompromised population have been a major concern for the government. This provides an opportunity for pharmaceutical players in the country to develop novel and more effective drugs for fungal diseases.
Anti-fungal Drugs Market Report contents include:
– Analysis of the Anti-fungal Drugs market including revenues, future growth, market outlook
– Historical data and forecast
– Regional analysis including growth estimates
– Analyzes the end user markets including growth estimates.
– Profiles on Anti-fungal Drugs including products, sales/revenues, and market position
– Market structure, market drivers and restraints.
Purchase this Report (Price 4250 USD for a Single-User License) – https://www.industryresearch.co/purchase/14099134
Detailed TOC of Anti-fungal Drugs Market Report Are:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness about the Myriad Fungal Infections
4.2.2 Increasing Number of Antifungal Drugs as Over-The-Counter (OTC)
4.2.3 Rising Consumption of Anti-fungal Drugs in Developing Regions for a Variety of Medical Conditions
4.3 Market Restraints
4.3.1 Medical Conditions
4.3.2 Increasing Resistance to Antifungal Drugs
4.3.3 Side Effects of Antifungal Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.5 Other Drug Type
5.2 By Indication
5.2.4 Other Indications
5.3 By Dosage Forms
5.3.4 Other Dosage Forms
5.4.1 North America
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.4.4 Middle East & Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle East & Africa
5.4.5 South America
18.104.22.168 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Astellas Pharma, Inc.
6.1.3 Bayer AG
6.1.4 GlaxoSmithKline Plc
6.1.6 Kramer Laboratories
6.1.7 Merck & Co., Inc.
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 SCYNEXIS, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports: